Manage episode 327115613 series 3328144
Dr. Jacob Glanville is founder and CEO of Centivax and founder of Distributed Bio, acquired by Charles River in 2021. His work focuses on understanding and engineering the repertoires of T and B cells to improve the response to pathogens. In this episode we discuss how to analyze receptor specificity and use this to create therapeutic antibodies and optimize vaccine response.
AIRR Community Meeting VI: “Exploring New Frontiers”: https://www.antibodysociety.org/the-airr-community/meetings/airr-community-meeting-vi-exploring-new-frontiers
iReceptor+ Seminar Series: http://www.ireceptor-plus.com/news-and-events/seminars
Comments are welcome to the inbox of firstname.lastname@example.org or on social media under the hashtag #onAIRR. Further information can be found here: https://www.antibodysociety.org/the-airr-community/airr-c-podcast